ROCKVILLE, Md., Feb. 27, 2024 (Globe Newswire) — MacroGenics, Inc. is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. (NASDAQ: MGNX) today, the company plans to announce its fourth quarter 2023 financial results after market close on Thursday, March 7, 2024. MacroGenics will host a conference call on Thursday, March 7, 2024 at 4:00 a.m. to discuss financial results and the company's recent progress. ET.
Teleconference information
If you would like to participate by phone, please register in advance here. Link. Once registered, all telephone participants will receive a confirmation email with details on how to join the conference call. This includes a dial-in number, a unique passcode and subscriber ID that you can use to access your phone. A listen-only webcast of the conference call will be accessible under “Events and Presentations” in the Investor Relations section of our website. http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available immediately after the call and will be archived on our website for 30 days after the call.
About Macrogenics Co., Ltd.
MacroGenics (the Company) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative monoclonal antibody-based therapeutics for the treatment of cancer. We primarily generate a pipeline of product candidates from our suite of proprietary next-generation antibody-based technology platforms that can be applied across a broad range of therapeutic areas. The combination of MacroGenics' technology platform and protein engineering expertise has enabled the company to generate promising product candidates and enter into several strategic alliances with global pharmaceutical and biotechnology companies. For more information, please visit our website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
CONTACT: CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
